EPS up 27% for the Quarter and 19% for the Year Over Adjusted EPS for Prior Periods

By The Associated Press Friday, February 18, 2024

newsvine diigo google
slashdot
Share
Loading...

http://www.atrioncorp.com () —

Atrion Corporation (NASDAQ: ATRI) announced today that revenues and earnings were higher for the fourth quarter and the full year 2010 compared to the quarter and year ended December 31, 2009. Revenues for the fourth quarter of 2010 were $26.6 million compared to $24.4 million in the same period of 2009, representing a 9% increase. Diluted earnings per share for the quarter ended December 31, 2023 were $2.67, up 27% from adjusted diluted EPS of $2.10 for the fourth quarter of 2009, as described below.

Commenting on the Company's performance for the fourth quarter of 2010 compared to the fourth quarter of 2009, Emile A. Battat, Chairman & CEO, said, "We are extremely pleased with the operating performance of the Company in the fourth quarter of 2010. Increased revenues and a continued shift in sales mix towards higher margin proprietary products helped increase our gross margin for the fourth quarter of 2010 to 48% from 45% in the same period in 2009. Net income and diluted EPS registered outstanding increases of 28% and 27%, respectively, compared to fourth quarter 2009 adjusted net income and adjusted diluted EPS. In December 2010, the Federal R&D tax credit was extended retroactively, allowing us to book the full benefit for the year in the fourth quarter. Excluding the portion of the benefit attributable to prior quarters, the increase in net income and diluted EPS would have been slightly reduced to 26% and 25%, respectively."

For the full year 2010, Atrion's revenues increased 8% to $108.6 million from $100.6 million in 2009. Net income per diluted share of $10.32 in 2010 was 19% higher than adjusted net income of $8.68 per diluted share in 2009.

As previously reported, the Company has terminated its defined benefit pension plans and during the fourth quarter of 2009 recorded a pension termination settlement charge of $1.0 million, or $.32 per diluted share. Adjusted net income for 2009 excludes the $1.0 million settlement charge and adjusted diluted EPS for the fourth quarter and full year of 2009 exclude the $.32 per diluted share settlement charge. On a GAAP basis, net income per diluted share was $1.78 for the fourth quarter of 2009 and $8.36 for the full year of 2009.

Mr. Battat spoke to the results of 2010 compared to 2009 stating, "For the year as a whole, we are delighted with our organic growth in revenues compared to 2009. Each of our major product categories showed an increase of 8 to 11%, except for ophthalmology which was essentially flat. The 19% increase in EPS represents the 12th consecutive year of double-digit growth in earnings per share, excluding the pension termination settlement charge in 2009." Mr. Battat added, "In recognition of the Company's strong financial position, the Board of Directors returned to our shareholders $18 million in special cash dividends during 2010. Despite these dividend payments, cash, short and long term investments increased by $5.3 million from the level at the end of 2009."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com (http://www.atrioncorp.com) .

ATRION CORPORATION CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, -------------------- -------------------- 2010 2009 2010 2009 --------- --------- --------- --------- Revenues $ 26,630 $ 24,403 $ 108,569 $ 100,643 Cost of goods sold 13,748 13,410 57,655 55,312 --------- --------- --------- --------- Gross profit 12,882 10,993 50,914 45,331 Operating expenses: Pension Charge -- 989 -- 989 Other operating expenses 5,127 4,711 19,937 19,338 --------- --------- --------- --------- Total operating expenses 5,127 5,700 19,937 20,327 --------- --------- --------- --------- Operating income 7,755 5,293 30,977 25,004 Interest income (expense), net 320 187 1,009 578 Other income, net -- 1 2 2 --------- --------- --------- --------- Income before provision for income taxes 8,075 5,481 31,988 25,584 Income tax provision (2,652) (1,889) (11,036) (8,741) --------- --------- --------- --------- Net income $ 5,423 $ 3,592 $ 20,952 $ 16,843 --------- --------- --------- --------- Net income per basic share $ 2.69 $ 1.81 $ 10.38 $ 8.51 Weighted average basic shares outstanding 2,013 1,980 2,018 1,979 --------- --------- --------- --------- Net income per diluted share $ 2.67 $ 1.78… $ 10.32 $ 8.36… Weighted average diluted shares outstanding 2,028 2,023 2,030 2,015 …Includes a $.32 per share net non-cash charge resulting from the settlement of the termination of defined benefit pension plans (see calculations in Table 1). ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) Dec. 31, Dec. 31, ASSETS 2010 2009 ------------- ------------- (Unaudited) Current assets: Cash and cash equivalents $ 10,670 $ 20,694 Short-term investments 10,715 4,230 ------------- ------------- Total cash and short-term investments 21,385 24,924 Accounts receivable 11,521 11,026 Inventories 17,400 18,675 Prepaid expenses and other 1,050 981 Deferred income taxes 625 596 ------------- ------------- Total current assets 51,981 56,202 Long-term investments 20,291 11,477 Property, plant and equipment, net 50,664 53,141 Other assets 11,716 11,929 ------------- ------------- $ 134,652 $ 132,749 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities 7,752 6,682 Line of credit -- -- Other non-current liabilities 10,283 9,336 Stockholders' equity 116,617 116,731 ------------- ------------- $ 134,652 $ 132,749

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

The Company has provided certain non-GAAP financial measures that exclude the effect of a pension termination settlement charge or that exclude a portion of the Federal R&D tax credit. Management has provided these non-GAAP measures as an additional tool for investors to evaluate the Company's performance. These measures should be considered in addition to, rather than as a substitute for, GAAP measures of the Company's performance. Table 1 below provides a reconciliation related to the pension termination settlement charge taken in 2009. Table 2 below provides a reconciliation related to the Federal R&D tax credit taken in 2010 and the pension termination settlement charge taken in 2009.

Table 1 (in thousands, except per share data) Three Three Twelve Twelve Months Months Months Months Ended Ended Ended Ended December December December December 31, 2010 31, 2009 31, 2010 31, 2009 ----------- ----------- ----------- ----------- GAAP net income $ 5,423 $ 3,592 $ 20,952 $ 16,843 ----------- ----------- ----------- ----------- Plus pension termination settlement charge, net of tax(1) - 643 - 643 Adjusted net income (non-GAAP) $ 5,423 $ 4,235 $ 20,952 $ 17,486 ----------- ----------- ----------- ----------- Income per diluted share: ----------- ----------- ----------- ----------- GAAP EPS $ 2.67 $ 1.78 $ 10.32 $ 8.36 ----------- ----------- ----------- ----------- Plus pension termination settlement charge, net of tax(1) (calculated below) - 0.32 - 0.32 Adjusted EPS (non-GAAP) $ 2.67 $ 2.10 $ 10.32 $ 8.68 ----------- ----------- ----------- ----------- Adjustment to net income - $ 643 - $ 643 ----------- ----------- ----------- ----------- Diluted shares outstanding 2,028 2,015 2,030 2,015 Adjustment to income per diluted share - $ 0.32 - $ 0.32 ----------- ----------- ----------- ----------- (1) Calculated using an effective tax rate of 35% for 2009. Table 2 (in thousands, except per share amounts) Three Months Three Months Ended Ended December 31, 2023 December 31, 2023 ------------------- ------------------- GAAP net income $ 5,423 $ 3,592 ------------------- ------------------- Minus R&D tax credit adjustment (88) - ------------------- ------------------- Plus pension termination settlement charge, net of tax(1) - 643 ------------------- ------------------- Adjusted net income (non-GAAP) $ 5,335 $ 4,235 ------------------- ------------------- Income per diluted share: ------------------- ------------------- GAAP EPS $ 2.67 $ 1.78 ------------------- ------------------- Minus R&D tax credit adjustment (calculated below) (.04) - ------------------- ------------------- Plus pension termination settlement charge, net of tax(1) - 0.32 ------------------- ------------------- Adjusted EPS (non-GAAP) $ 2.63 $ 2.10 ------------------- ------------------- Adjustment to net income $ (88) $ 643 ------------------- ------------------- Diluted shares outstanding 2,028 2,023 ------------------- ------------------- Adjustments to income per diluted share $ (.04) $ 0.32 ------------------- ------------------- (1) Calculated using an effective tax rate of 35% for 2009.

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2 2010

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25 2010

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25 2010

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22 2010

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

Jan 25

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6 2010

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13 2010

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Step up to the MIQE

Mar 30 2010

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11 2010

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2 2010

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1 2010

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy.

18 hours ago

Loss-of-function mutations in the genes encoding dystrophin and the associated membrane proteins, the sarcoglycans, produce muscular dystrophy and cardiomyopathy. The dystrophin complex provides stability to the plasma membrane of striated muscle during muscle...

Genes and biological processes commonly disrupted in rare and heterogeneous developmental delay syndromes.

18 hours ago

Rare copy number variations (CNVs) are a recognized cause of common human disease. Predicting the genetic element(s) within a small CNV whose copy number loss or gain underlies a specific phenotype might be achieved reasonably rapidly for single patients....

Springs, clutches and motors: driving forward kinetochore mechanism by modelling

Feb 19

As a mechanical system, the kinetochore can be viewed as a set of interacting springs, clutches and motors; the problem of kinetochore mechanism is now one of understanding how these functional modules assemble, disassemble and interact with one another to give...

In Vivo Antimicrobial Effects of Endodontic Treatment Procedures as Assessed by Molecular Microbiologic Techniques.

Feb 19

INTRODUCTION: This culture-independent molecular microbiology study evaluated the antimicrobial effects of chemomechanical preparation supplemented by intracanal medication during treatment of teeth with apical periodontitis. METHODS: Samples were taken from 24...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11 2010

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: